| Variable | Categories | Reduced eGFR | OR (95% CI) | p-value | |
| Yes (n = 6) | No (n = 54) | ||||
| n (%) | n (%) | ||||
| Age (Years) | <60 | 2 (33.3) | 11 (20.4) | 1 | 0.471 |
| ≥60 | 4 (66.7) | 43 (79.6) | 1.96 [0.32 - 12.0] | ||
| Sex | Male | 3 (50) | 38 (70.4) | 0.42 [0.08 - 2.31] | 0.320 |
| Female | 3 (50) | 16 (26.9) | 1 | ||
| Medication | ARB use | 0 (0) | 5 (8.4) | Undefined | 0.999 |
| ACEI use | 2 (33.3) | 6 (11.1) | 4.00 [0.60 - 26.68] | 0.152 | |
| NSAIDS use | 1 (16.7) | 3 (5.6) | 3.40 [0.30 - 39.10] | 0.326 | |
| Diuretics use | 2 (33.3) | 3 (5.6) | 8.50 [1.09 - 6.58] | 0.042 | |
| Herbal med use | 1 (16.7) | 12 (22.2) | 0.70 [0.07 - 6.58] | 0.755 | |
| TFV prodrug | TDF | 5 (83.3) | 37 (40.7) | 2.30 [0.25 - 21.2] | 0.463 |
| TAF | 1 (16.7) | 17 (31.5) | 1 | ||
| Comorbidities | Hypertension | 2 (33.3) | 10 (18.5) | 2.20 [0.35 - 13.7] | 0.399 |
| Diabetes | 0 (0) | 7 (13) | Undefined | 0.999 | |
| HDV | 3 (50) | 17 (31.5) | 2.18 [0.40 - 1.92] | 0.370 | |
| BMI (kg/m2) | <18 | 1 (16.7) | 2 (3.7) | 5.20 [0.40 - 7.94] | 0.209 |
| ≥18 | 5 (83.3) | 52 (96.3) | 1 | ||
| Duration of TFV therapy (months) | <36 | 4 (66.7) | 3 (5.6) | 1 | 0.001 |
| ≥36 | 2 (33.3) | 51 (94.4) | 34.00 [4.34 - 266.3] |
| |
| ALAT, IU/L | >36 | 3 (50) | 27 (50) | 1.00 [0.19 - 5.40] | 1.000 |
| ≤36 | 3 (50) | 27 (50) | 1 | ||
| ASAT, IU/L | >35 | 3 (50) | 26 (48.1) | 1.08 [0.20 - 5.82] | 0.931 |
| ≤35 | 3 (50) | 28 (51.9) | 1 | ||
| Hepatitis B viral load, IU/mL | >2000 | 3 (50) | 23 (43.4) | 1.30 [0.24 - 7.07] | 0.78 |
| ≤2000 | 3 (50) | 30 (56.6) | 1 | ||